1h Free Analyst Time
The publisher's latest Pharmaceutical and Healthcare disease pipeline guide Critical Limb Ischemia - Drugs In Development, 2022, provides an overview of the Critical Limb Ischemia (Cardiovascular) pipeline landscape.Speak directly to the analyst to clarify any post sales queries you may have.
Critical limb ischemia (CLI) is the most severe form of peripheral arterial disease (PAD). It is caused by chronic inflammatory processes associated with atherosclerosis that result in reduced blood flow to the legs, feet and hands. Symptoms include pain or numbness in feet or toes, sores, skin infections will not heal. Treatment goals for CLI include reducing the number of cardiovascular risk factors (such as quitting smoking and reduction of cholesterol), relieving pain, healing ulcers, preventing major amputation, improving quality of life and increasing survival.
Report Highlights
The publisher's Pharmaceutical and Healthcare latest pipeline guide Critical Limb Ischemia - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Critical Limb Ischemia (Cardiovascular), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.The Critical Limb Ischemia (Cardiovascular) pipeline guide also reviews of key players involved in therapeutic development for Critical Limb Ischemia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 3, 12, 1, 2, 8, 1 and 1 respectively. Similarly, the Universities portfolio in Phase II and Preclinical stages comprises 1 and 1 molecules, respectively.
Critical Limb Ischemia (Cardiovascular) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Critical Limb Ischemia (Cardiovascular).
- The pipeline guide reviews pipeline therapeutics for Critical Limb Ischemia (Cardiovascular) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Critical Limb Ischemia (Cardiovascular) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Critical Limb Ischemia (Cardiovascular) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Critical Limb Ischemia (Cardiovascular)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Critical Limb Ischemia (Cardiovascular).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Critical Limb Ischemia (Cardiovascular) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
- Introduction
- Report Coverage
- Critical Limb Ischemia - Overview
- Critical Limb Ischemia - Therapeutics Development
- Pipeline Overview
- Pipeline by Companies
- Pipeline by Universities/Institutes
- Products under Development by Companies
- Products under Development by Universities/Institutes
- Critical Limb Ischemia - Therapeutics Assessment
- Assessment by Target
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Critical Limb Ischemia - Companies Involved in Therapeutics Development
- Critical Limb Ischemia - Drug Profiles
- Critical Limb Ischemia - Dormant Projects
- Critical Limb Ischemia - Discontinued Products
- Critical Limb Ischemia - Product Development Milestones
- Featured News & Press Releases
- May 10, 2022: Hemostemix announces its intellectual property is back home
- Mar 24, 2022: Hemostemix announces settlement agreement
- Sep 08, 2021: Ixaka announces positive interim Phase 3 clinical trial data for its lead cell therapy candidate REX-001
- Jul 06, 2021: Hemostemix provides update of Phase II clinical trial, 9th Circuit Court Decision including Cost Award and its Annual General Meeting Results
- Apr 23, 2021: Hemostemix announces completion of phase II clinical trial subject follow up & HMTXF Up-list
- Mar 18, 2021: Hemostemix announces clinical trial update and contract with Globex data to encrypt its communications with regulatory authorities
- Jan 28, 2021: Hemostemix announces HS 12 - 01 clinical trial completion of subjects’ follow-up visits at the end of march and warrants extented and repriced
- Oct 26, 2020: Rexgenero announces positive outcome of independent data monitoring committee meeting for phase III trial for diabetic patients with critical limb-threatening ischaemia
- Sep 09, 2020: Caladrius Biosciences announces registration of HONEDRA trademark and new patent in Japan
- Jul 06, 2020: Aspire Health Science, announces release of ACP-01 midpoint analysis to Hemostemix
- Apr 01, 2020: Cynata provides guidance on planned CLI clinical trial
- Mar 03, 2020: Canadian patent issued for Cynata Therapeutics unique stem cell technology
- Jan 26, 2020: Hemostemix provides corporate update and clarification
- Jan 14, 2020: UK regulatory authority approves Cynata’s phase 2 clinical trial in critical limb ischaemia
- Nov 25, 2019: Cynata files application to commence phase 2 clinical trial in critical limb ischaemia
- Appendix
- Methodology
- Coverage
- Secondary Research
- Primary Research
- Expert Panel Validation
- Contact the Publisher
- Disclaimer
- Number of Products under Development for Critical Limb Ischemia, 2022
- Number of Products under Development by Companies, 2022
- Number of Products under Development by Universities/Institutes, 2022
- Products under Development by Companies, 2022
- Products under Development by Companies, 2022 (Contd..1)
- Products under Development by Universities/Institutes, 2022
- Number of Products by Stage and Target, 2022
- Number of Products by Stage and Mechanism of Action, 2022
- Number of Products by Stage and Route of Administration, 2022
- Number of Products by Stage and Molecule Type, 2022
- Critical Limb Ischemia - Dormant Projects, 2022
- Critical Limb Ischemia - Dormant Projects, 2022 (Contd..1)
- Critical Limb Ischemia - Dormant Projects, 2022 (Contd..2)
- Critical Limb Ischemia - Discontinued Products, 2022
- Number of Products under Development for Critical Limb Ischemia, 2022
- Number of Products under Development by Companies, 2022
- Number of Products under Development by Universities/Institutes, 2022
- Number of Products by Targets, 2022
- Number of Products by Stage and Targets, 2022
- Number of Products by Mechanism of Actions, 2022
- Number of Products by Stage and Mechanism of Actions, 2022
- Number of Products by Routes of Administration, 2022
- Number of Products by Stage and Routes of Administration, 2022
- Number of Products by Molecule Types, 2022
- Number of Products by Stage and Molecule Types, 2022
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Ambulero Inc
- Antidote Therapeutics Inc
- Athersys Inc
- Caladrius Biosciences Inc
- Constant Therapeutics LLC
- Cynata Therapeutics Ltd
- Gurus BioPharm Inc
- Helixmith Co Ltd
- Hemostemix Inc
- ID Pharma Co Ltd
- ImmuneCyte Inc
- Ixaka Ltd
- Kangstem Biotech Co Ltd
- Libella Gene Therapeutics
- New Beta Innovation Ltd
- Orgenesis Inc
- Pharmicell Co Ltd
- Pluri Inc
- Reven Holdings Inc
- S.Biomedics Co Ltd
- Taiwan Bio Therapeutics Co Ltd
- Theratome Bio Inc
- VESSL Therapeutics Ltd
- Vivazome Therapeutics Pty Ltd
- Yichang Humanwell Pharmaceutical Co Ltd
